Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001628280-22-017114
Filing Date
2022-06-14
Accepted
2022-06-14 16:08:58
Documents
13
Period of Report
2022-06-09
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K/A crdf-20220609.htm   iXBRL 8-K/A 61522
5 crdf-20220609_g1.jpg GRAPHIC 176318
  Complete submission text file 0001628280-22-017114.txt   632585

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT crdf-20220609.xsd EX-101.SCH 1929
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT crdf-20220609_lab.xml EX-101.LAB 22963
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT crdf-20220609_pre.xml EX-101.PRE 12087
7 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20220609_htm.xml XML 10067
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-35558 | Film No.: 221014810
SIC: 2836 Biological Products, (No Diagnostic Substances)